Cynata Appoints Dr Geoff Brooke as Chairman
Filed with ASX · · 2 pages · English
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cynata Announces Positive Results from GvHD Trial Follow-up
- Ethics Approval & Expedited Pathway for Phase 3 OA Trial
- Block Trade Proceeds to Reduce Director Loans
- Cynata Successfully Completes Share Purchase Plan
- Ethics Approval to Commence Clinical Trial in COVID-19
Later from Cynata Therapeutics
- Patient Enrolment Opens in COVID-19 Clinical Trial
- Cymerus MSCs Effective in Preclinical Lung Disease Study
- Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
- Potential Utility of Cymerus MSCs in Heart Attack Model
- Phase 3 Osteoarthritis Clinical Trial Commences
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics